Korean Circ J.  2018 Mar;48(3):233-235. 10.4070/kcj.2018.0032.

Chromosomal Microarray: Application for Congenital Heart Diseases

• Ko JM

• KMID: 2406928
• DOI: http://doi.org/10.4070/kcj.2018.0032

Abstract

No abstract available.

MeSH Terms

Heart Diseases*
Heart*

Reference

1. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010; 86:749–764.

2. Manning M, Hudgins L; Professional Practice and Guidelines Committee. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med. 2010; 12:742–745.

3. Coulter ME, Miller DT, Harris DJ, et al. Chromosomal microarray testing influences medical management. Genet Med. 2011; 13:770–776.

4. Battaglia A, Doccini V, Bernardini L, et al. Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features. Eur J Paediatr Neurol. 2013; 17:589–599.

5. Bejjani BA, Saleki R, Ballif BC, et al. Use of targeted array-based CGH for the clinical diagnosis of chromosomal imbalance: is less more? Am J Med Genet A. 2005; 134:259–267.

6. Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA. 2004; 101:17765–17770.

7. Stankiewicz P, Beaudet AL. Use of array CGH in the evaluation of dysmorphology, malformations, developmental delay, and idiopathic mental retardation. Curr Opin Genet Dev. 2007; 17:182–192.

8. Keren B. The advantages of SNP arrays over CGH arrays. Mol Cytogenet. 2014; 7:I31.

9. Choi BG, Hwang SK, Kwon JE, Kim YH. Array comparative genomic hybridization as the first-line investigation for neonates with congenital heart disease: experience in a single tertiary center. Korean Circ J. 2018; 48:209–216.